Dapagliflozin's Association With Cardiorenal Outcomes and Apolipoprotein M Levels in HFrEF Patients : Insights From DEFINE-HF
BACKGROUND: Apolipoprotein M (ApoM) is associated with lower mortality in heart failure (HF) patients and protects against cardiac and kidney injury in mice.OBJECTIVES: The authors investigated dapagliflozin's cardiorenal effects by studying its association with ApoM in patients with HF with reduced ejection fraction.METHODS: We performed a secondary analysis of DEFINE-HF (Dapagliflozin Effects on